** Shares in Nanobiotix NANOB.PA rise around 9% after French magazine La Lettre reported J&J JNJ.N is considering a takeover of the French nanomedicine company
** Neither company immediately responded to Reuters requests for comment
** Analysts from Kempen Life Sciences Research say in a note that a takeover at this stage is unlikely, given that under the companies' current partnership, J&J has the exclusive license to experimental cancer treatment NBTXR3
** Up to Tuesday's close, Nanobiotix's shares were up around 30% YTD
(Reporting by Mateusz Rabiega)
((Mateusz.rabiega@thomsonreuters.com))